Who has invested the most in R&D among the 14 listed pharmaceutical companies with revenues exceeding RMB 10 billion?

Wonderful content passed quietly in the first quarter of 2017, and the disclosure of 2016 annual report of listed pharmaceutical companies was coming to an end, and the report card of a number of pharmaceutical giants jumped onto the paper Up to now, there are 14 companies with revenues of over 10 billion, among which Shanghai Pharmaceutical continues to take pride in the group with revenues of over 100 billion In the aspect of R & D investment, Hengrui pharmaceutical takes the lead, followed by Fosun Pharmaceutical, Shanghai pharmaceutical, humanwell pharmaceutical, etc 1497.5 billion yuan! In 2016, China's drug market cake increased by 8.3% year-on-year (click the topic to read directly) table 1: overview of listed drug companies with revenue exceeding 10 billion yuan (unit: 100 million yuan) As of April 11, there were 14 domestic drug companies with revenue exceeding 10 billion yuan Among them, Shanghai Pharmaceutical is the best in the world, with a revenue of 120.765 billion yuan, an increase of 14.45% year on year The largest R & D investment is Hengrui pharmaceutical, up to 1.184 billion yuan, followed by Fosun Pharmaceutical, Shanghai Pharmaceutical and humanwell pharmaceutical For the pharmaceutical industry, when it comes to domestic R & D, the first thing that comes to mind is Hengrui Hengrui pharmaceutical has become a worthy R & D king among domestic pharmaceutical enterprises At the same time, due to the excellent R & D fist, Hengrui's revenue data is also eye-catching According to the 2016 annual report of Hengrui pharmaceutical, its operating revenue was 11.094 billion yuan, an increase of 19.08% compared with the same period in 2015, which was gratifying Figure 1: R & D investment of Hengrui pharmaceutical in recent years (unit: 10000 yuan) in 2016, Hengrui has invested 1.184 billion yuan in R & D, an increase of 32.82% over the same period of last year The high growth of R & D investment is amazing It is reported that Hengrui has kept its R & D investment at about 10% of its revenue for a long time, which ranks first among a number of pharmaceutical listed companies, and its R & D level and achievements are far ahead of the others At present, Hengrui focuses on the fields of antineoplastic drugs, surgical anesthetics, contrast agents, major diseases and no effective treatment drugs, forming a huge product development pipeline Hengrui's innovation model has gradually moved from "me too" and "me better" in the early stage of innovation to source innovation, and the layout of innovative drugs is transforming from small molecule drugs to large molecule drugs Up to now, two innovative drugs of Hengrui, irexib and apatinib, have been on the market In 2016, the company introduced oncolytic adenovirus products from Japan's o ncolys biopharma for development in China Table 2: investment in R & D of Hengrui's main products The R & D output of Fosun Pharma's overseas market continues to break out In 2016, Fosun Pharma achieved an operating revenue of RMB 14.629 billion, an increase of 16.02% over 2015 It is worth noting that Fosun Pharmaceutical has achieved a revenue of 2122.35 million yuan in overseas countries or regions, an increase of 25.37% compared with 2015, and the revenue growth of overseas countries or regions has further increased This is closely related to the two wheel drive strategy of "endogenous growth plus extended expansion" adopted by Fosun Pharmaceutical in recent years In addition to the outbreak of overseas markets and endogenous growth, innovation and R & D are the most core development driving factors, and they are continuously invested in the R & D field of superior products with precise effect and in line with the development orientation of modern medicine In 2016, Fosun's R & D investment (including capitalization) totaled RMB 1.106 billion, an increase of 33.23% over 2015, of which the R & D investment in the pharmaceutical manufacturing and R & D sector was RMB 963.14 million, an increase of 38.03% over 2015 Figure 2: R & D investment of Fosun Pharmaceutical in recent years (unit: 10000 yuan) In recent years, the R & D investment of Fosun Pharmaceutical accounts for about 1% of the industrial operating revenue After continuous high-intensity R & D investment, its innovative products gradually enter the harvest period At present, Fosun Pharmaceutical has 173 projects under research, 6 clinical applications, 22 clinical applications and 42 listing applications It is worth noting that the company's mAb research and development ability is strong, and it is in the leading position in China Six mAbs have entered the clinical stage, among which the heavy-duty recombinant human mouse chimeric anti-CD20 mAb and recombinant anti HER2 humanized mAb have entered the clinical stage III, and are expected to be approved and listed first The R & D investment of Shanghai pharmaceutical giant remains high If there are several pharmaceutical giants, Shanghai Pharmaceutical is the leading super giant in terms of revenue alone After its revenue of more than 100 billion yuan in 2015, it reached a new high of nearly 120.765 billion yuan in 2016, which is really beyond the reach of other pharmaceutical companies Figure 3: the R & D investment of Shanghai Pharmaceutical in recent years (unit: 10000 yuan) is still at a high level in 2016, compared with 618 million yuan in 2015, excluding the investment in the construction of the company's pilot test base, totaling 671 million yuan, accounting for 5.40% of the company's industrial sales revenue Among them, 23.12% went to the research and development of innovative drugs, 20.77% to the research and development of generic drugs, 48.20% to the secondary development of existing products, and 7.91% to the consistency evaluation of the quality and efficacy of generic drugs
In 2016, Shanghai Pharmaceutical Research and development achieved a number of phased results The recombinant anti-CD20 humanized monoclonal antibody injection, sph3127 and sph1188-11 obtained clinical approval, the application for clinical acceptance of the recombinant anti-HER2 humanized monoclonal antibody composition for injection, the clinical approval of 17 generic drugs, the production approval of 5 varieties, and the approval of salvianolic acid A for injection of a new class of traditional Chinese medicine Clinical approval documents and rosuvastatin calcium tablets were approved by FDA At the same time, SHP also focused on promoting the consistency evaluation of quality and efficacy of generic drugs At present, it has completed the first batch of 70 varieties, determined 15 universities and R & D companies as technical service suppliers, established the purchasing Bank of Shanghai pharmaceutical reference preparations, determined 32 intended varieties and signed strategic framework agreements with 10 top three hospitals in Shanghai to carry out clinical trial cooperation The export business of humanwell pharmaceutical has steadily promoted R & D overseas In 2016, humanwell pharmaceutical achieved an operating revenue of about 12.3 billion yuan, an increase of 22.65% over the same period of last year, with a remarkable growth rate Among them, humanwell's overseas business has been steadily promoted, covering mature markets in Europe and the United States, South America, Southeast Asia, West Africa and other regions At present, humanwell has nearly 20 anda numbers issued by the U.S FDA, and about 400 drugs are sold in the U.S market The company's narcotic drugs and birth control drugs have been approved to enter the Southeast Asia and European markets successively; The company's pharmaceutical factory in Mali, Africa was put into production at the end of 2015, and its international business has entered a stage of rapid development Figure 4: R & D investment of humanwell pharmaceutical in recent years (unit: 10000 yuan) In addition to the amazing achievements in the export of preparations, humanwell pharmaceutical's R & D is also overseas oriented According to the annual report, the R & D expenditure of humanwell pharmaceutical in 2016 was 502 million yuan, an increase of 24.37% year on year, accounting for 4.07% of the operating revenue of the year Among the products under research of humanwell pharmaceutical, there are more than 200 projects under research in China and 21 new drug projects under research, among which 7 projects have obtained 10 clinical trial approvals, 1 project has entered phase III clinical trial, and 2 projects have completed phase II clinical trial; while there are more than 80 products under research in the United States, 12 of which have been declared to FDA are waiting for approval of Anda Conclusion: in today's innovation oriented situation, pharmaceutical research and development is undoubtedly the core driving force for the future survival and development of pharmaceutical enterprises The development of science and technology and the innovation of policies create a better and better environment for the research and development of pharmaceutical enterprises Looking at domestic leading pharmaceutical enterprises, most of their revenue is directly proportional to R & D investment, and R & D leading the future has become the industry consensus In the future, we will see where the research and development of domestic pharmaceutical enterprises will go and how much they will get Source: annual report of listed company